$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000161883519000170 Filed on November 07, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue		$0.00
YoY Change
Gross Profit		$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.440M	$8.634M	$5.210M
YoY Change	81.19%	0.63%	157.92%
% of Gross Profit
Research & Development	$3.430M	$5.663M	$9.770M
YoY Change	-64.89%	-42.51%	2691.43%
% of Gross Profit
Depreciation & Amortization	$60.00K	$70.00K	$60.00K
YoY Change	0.0%	0.0%	200.0%
% of Gross Profit
Operating Expenses	$12.87M	$14.30M	$14.98M
YoY Change	-14.08%	-22.44%	-2.38%
Operating Profit		-$14.30M
YoY Change		-22.44%
Interest Expense	$120.0K	$210.0K	$30.00K
YoY Change	300.0%	425.0%	200.0%
% of Operating Profit
Other Income/Expense, Net	$155.0K	$499.0K	$0.00
YoY Change		24850.0%	-100.0%
Pretax Income	-$12.72M	-$13.80M	-$14.98M
YoY Change	-15.09%	-25.14%	534.75%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$12.72M	-$13.80M	-$14.98M
YoY Change	-15.11%	-25.14%	-23.15%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$251.2K	-$298.4K	-$579.3K
COMMON SHARES
Basic Shares Outstanding	46.81M shares	46.60M shares	25.87M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.80M	$35.80M	$1.300M
YoY Change	1730.77%	195.87%	-61.76%
Cash & Equivalents	$15.57M	$32.12M	$1.330M
Short-Term Investments	$8.200M	$3.700M
Other Short-Term Assets	$1.900M	$1.500M	$700.0K
YoY Change	171.43%	50.0%	16.67%
Inventory	$0.00
Prepaid Expenses
Receivables	$0.00
Other Receivables
Total Short-Term Assets	$26.42M	$37.53M	$2.478M
YoY Change	966.22%	179.59%	5.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$394.0K	$546.0K	$593.0K
YoY Change	-33.56%	-16.26%	-30.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.320M	$596.0K	$939.0K
YoY Change	40.58%	-37.26%	25.2%
Total Long-Term Assets	$1.874M	$1.457M	$1.532M
YoY Change	22.32%	-9.05%	-4.13%
TOTAL ASSETS
Total Short-Term Assets	$26.42M	$37.53M	$2.478M
Total Long-Term Assets	$1.874M	$1.457M	$1.532M
Total Assets	$28.30M	$38.99M	$4.010M
YoY Change	605.61%	159.48%	1.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.008M	$5.163M	$8.882M
YoY Change	-32.36%	-35.74%	-1.3%
Accrued Expenses	$2.784M	$6.453M	$11.51M
YoY Change	-75.82%	-55.33%	-4.74%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$4.000M
YoY Change	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.66M	$14.91M	$27.33M
YoY Change	-53.68%	-40.44%	-73.56%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.66M	$14.91M	$27.33M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$12.66M	$14.91M	$27.37M
YoY Change	-53.74%	-40.56%	-73.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$513.2M	-$500.5M	-$433.1M
YoY Change	18.48%	19.68%	40.96%
Common Stock	$528.8M	$524.5M	$409.8M
YoY Change	29.05%	28.53%	2211.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.64M	$24.08M	-$23.36M
YoY Change
Total Liabilities & Shareholders Equity	$28.30M	$38.99M	$4.010M
YoY Change	605.61%	159.48%	1.47%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q4
OPERATING ACTIVITIES
Net Income	-$12.72M	-$13.80M	-$14.98M
YoY Change	-15.11%	-25.14%	-23.15%
Depreciation, Depletion And Amortization	$60.00K	$70.00K	$60.00K
YoY Change	0.0%	0.0%	200.0%
Cash From Operating Activities	-$13.45M	-$14.42M	-$10.25M
YoY Change	31.22%	61.66%	334.32%
INVESTING ACTIVITIES
Capital Expenditures	-$140.0K	-$20.00K	-$10.00K
YoY Change	1300.0%
Acquisitions
YoY Change
Other Investing Activities	-$4.480M	-$3.720M	$0.00
YoY Change
Cash From Investing Activities	-$4.630M	-$3.740M	-$10.00K
YoY Change	46200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.200M	-420.0K	-500.0K
YoY Change	-540.0%	-77.89%	-1766.67%
NET CHANGE
Cash From Operating Activities	-13.45M	-14.42M	-10.25M
Cash From Investing Activities	-4.630M	-3.740M	-10.00K
Cash From Financing Activities	2.200M	-420.0K	-500.0K
Net Change In Cash	-15.88M	-18.58M	-10.76M
YoY Change	47.58%	71.72%	361.8%
FREE CASH FLOW
Cash From Operating Activities	-$13.45M	-$14.42M	-$10.25M
Capital Expenditures	-$140.0K	-$20.00K	-$10.00K
Free Cash Flow	-$13.31M	-$14.40M	-$10.24M
YoY Change	29.98%	61.43%	333.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001618835
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	46810803	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	EVOFEM BIOSCIENCES, INC.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	9153000	USD
CY2019Q3	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	3121000	USD
CY2018Q4	evfm	Accrued Interest Unpaid Sublicense Fees AccruedInterestUnpaidSublicenseFees	174000	USD
CY2019Q3	evfm	Accrued Interest Unpaid Sublicense Fees AccruedInterestUnpaidSublicenseFees	0	USD
CY2018Q4	evfm	Accrued Manufacturing Related Costs Current AccruedManufacturingRelatedCostsCurrent	0	USD
CY2019Q3	evfm	Accrued Manufacturing Related Costs Current AccruedManufacturingRelatedCostsCurrent	2033000	USD
CY2018Q4	evfm	Accrued Sublicense Fees AccruedSublicenseFees	1117000	USD
CY2019Q1	evfm	Accrued Sublicense Fees AccruedSublicenseFees	1300000	USD
CY2019Q3	evfm	Accrued Sublicense Fees AccruedSublicenseFees	0	USD
CY2019Q2	evfm	Adjustments To Additional Paidin Capital Reclassification Of Purchase Rights Liability AdjustmentsToAdditionalPaidinCapitalReclassificationOfPurchaseRightsLiability	22800000	USD
CY2019Q2	evfm	Adjustments To Additional Paidin Capital Reclassification Of Warrants AdjustmentsToAdditionalPaidinCapitalReclassificationOfWarrants	6900000	USD
CY2019Q2	evfm	Adjustments To Additional Paidin Capital Reclassificationof Warrants And Purchase Rights Liability AdjustmentsToAdditionalPaidinCapitalReclassificationofWarrantsAndPurchaseRightsLiability	29726000	USD
CY2018Q2	evfm	Class Of Warrant Or Right Issued In Transaction ClassOfWarrantOrRightIssuedInTransaction	8500000	shares
CY2019Q3	evfm	Common Stock Reserved Upon Release Of Restricted Stock Units CommonStockReservedUponReleaseOfRestrictedStockUnits	113000	shares
CY2018Q1	evfm	Deemed Contribution Upon Exchange Of Preferred Stock DeemedContributionUponExchangeOfPreferredStock	49334000	USD
	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	536000	USD
	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	50000	USD
	evfm	Deferred Rent Adjustment DeferredRentAdjustment	229000	USD
	evfm	Deferred Rent Adjustment DeferredRentAdjustment	0	USD
CY2018Q3	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	0	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11513000	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Annual Principal Payment DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableAnnualPrincipalPayment	300000	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6453000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	549000	USD
CY2019Q2	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	19600000	USD
CY2019Q2	evfm	Warrant Liability WarrantLiability	3600000	USD
	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	0	USD
CY2018Q1	evfm	Warrants And Stock Issued During Period Value New Issues WarrantsAndStockIssuedDuringPeriodValueNewIssues	14062000	USD
CY2019Q1	evfm	Warrants And Stock Issued During Period Value New Issues WarrantsAndStockIssuedDuringPeriodValueNewIssues	10617000	USD
CY2019Q3	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	0	USD
CY2019Q3	evfm	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	22600000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8882000	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Stated Rate DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableStatedRate	0.05
	evfm	Fair Value Adjustment Of Purchase Rights FairValueAdjustmentOfPurchaseRights	19617000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5163000	USD
	evfm	Gain Loss On Issuance Of Convertible Preferred Stock GainLossOnIssuanceOfConvertiblePreferredStock	-47920000	USD
	evfm	Gain Loss On Issuance Of Convertible Preferred Stock GainLossOnIssuanceOfConvertiblePreferredStock	0	USD
	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	0	USD
	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	576000	USD
CY2015Q1	evfm	Lessee Operating Lease Renewal Options LesseeOperatingLeaseRenewalOptions	2	renewal_term
CY2019Q2	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	700000	USD
CY2018Q3	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	0	USD
	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	0	USD
CY2019Q3	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	0	USD
	evfm	Loss On Issuance Of Purchase Rights LossOnIssuanceOfPurchaseRights	674000	USD
CY2018Q3	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	47920000	USD
CY2019Q3	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
	evfm	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	USD
CY2018Q4	evfm	Notes Issued Stated Rate Monthly Percent Of Principal Permitted NotesIssuedStatedRateMonthlyPercentOfPrincipalPermitted	0.01
	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	37542000	USD
	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
CY2019Q2	evfm	Purchase Right Liability PurchaseRightLiability	3200000	USD
	evfm	Reclassification Of Warrants And Purchase Rights To Equity ReclassificationOfWarrantsAndPurchaseRightsToEquity	0	USD
	evfm	Reclassification Of Warrants And Purchase Rights To Equity ReclassificationOfWarrantsAndPurchaseRightsToEquity	6120000	USD
CY2019Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	687000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	604000	USD
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	802000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	409787000	USD
CY2019Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	524532000	USD
CY2018Q3	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-1526000	USD
CY2019Q1	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-6000	USD
CY2019Q2	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-518000	USD
CY2019Q3	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-122000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	80000000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	688000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10663000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4735000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1962000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2515000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2263000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4735000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16086000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2263000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6740000	USD
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9414210	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9414210	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13182426	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13182426	shares
CY2018Q4	us-gaap	Assets Assets	4010000	USD
CY2019Q3	us-gaap	Assets Assets	38989000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	2478000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	37532000	USD
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	904000	USD
CY2019Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	25520000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	127000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	1900000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12076000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1330000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32120000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32100000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12522000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32506000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1701000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12522000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1761000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	32506000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	10821000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	30745000	USD
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.67
CY2019Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6168815	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13583087	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25867248	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46791230	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25867248	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46791230	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	5000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	207000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	408000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8634000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21072000	USD
CY2018Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	0	USD
CY2017Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	80	shares
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	37000	USD
CY2019Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	196000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	198000	USD
CY2018Q3	us-gaap	Depreciation Nonproduction DepreciationNonproduction	100000	USD
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	200000	USD
CY2019Q3	us-gaap	Depreciation Nonproduction DepreciationNonproduction	100000	USD
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	200000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1300000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	1900000	USD
CY2017Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	5200000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.38
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.83
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2924000	USD
CY2019Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2916000	USD
CY2019Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3300000	USD
CY2018Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2019Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	7755000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8582000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29018000	USD
CY2019Q3	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	3715000	USD
CY2019Q3	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Gain HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain	3000	USD
CY2019Q3	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	3718000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18431000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-110729000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13798000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-67312000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1501000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3628000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2139000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-5186000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-56000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-8000	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	35000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4010000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38989000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	27329000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14914000	USD
CY2018Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-130000	USD
CY2019Q3	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2018Q4	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2019Q3	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54924000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	75884000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2150000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3488000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	97000	USD
CY2019Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	212000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	338000	USD
	us-gaap	Lease Cost LeaseCost	0	USD
	us-gaap	Lease Cost LeaseCost	487000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	395000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	201000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	194000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13000	USD
CY2015Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P0Y6M
CY2018Q4	us-gaap	Liabilities Liabilities	27366000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	14914000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46253000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41651000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-69056000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-23244000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-18431000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-110731000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-18068000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-35450000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-13798000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-67316000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18431000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-110797000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13798000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-67316000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	46000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-48068000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-115000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	287000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	266000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	499000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-27442000	USD
CY2018Q4	us-gaap	Notes Issued1 NotesIssued1	4000000	USD
CY2018Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4010000	USD
CY2019Q3	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	18433000	USD
	us-gaap	Operating Expenses OperatingExpenses	62661000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	14297000	USD
	us-gaap	Operating Expenses OperatingExpenses	39870000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18433000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-62661000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-14297000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39870000	USD
CY2018Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	135000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	389000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	186000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	563000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	400000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	382000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	382000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	640000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	315000	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	300000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	978000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	777000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	201000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	520000	USD
CY2019Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	612000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	939000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	596000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-33000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6273000	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	200000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	157000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	USD
CY2018Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	977000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1180000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1526000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	645000	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	USD
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	3715000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	717000	USD
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1311000	USD
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	20000000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	75400000	USD
CY2016Q3	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	600000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	46000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1197000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1348000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	593000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	546000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4010000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9851000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33643000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5663000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18798000	USD
CY2018Q3	us-gaap	Restricted Cash RestrictedCash	446000	USD
CY2019Q3	us-gaap	Restricted Cash RestrictedCash	386000	USD
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	431000	USD
CY2019Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	386000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-433146000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-500462000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-500500000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	802000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	16086000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6740000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate	0.15
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1147895	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4418300	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	733000	shares
CY2018Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	121315000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	5226000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	46000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-289546000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-18292000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	5258000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	-10065000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-23356000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-28851000	USD
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	290000	shares
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	35792000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	24075000	USD
CY2018Q1	us-gaap	Stockholders Equity Change In Reporting Entity StockholdersEquityChangeInReportingEntity	1946000	USD
CY2018Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	166.7000
CY2018Q1	us-gaap	Temporary Equity Accretion Of Dividends TemporaryEquityAccretionOfDividends	223000	USD
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2019Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2018Q3	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	66000	USD
CY2019Q3	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
CY2018Q1	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	14100000	USD
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25778316	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20580017	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46239225	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36760013	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances due to the financial position of the depository institutions in which these deposits are held.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the notes thereto.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:9pt;">S</font><font style="font-family:inherit;font-size:10pt;">ignificant estimates affecting amounts reported or disclosed in the consolidated financial statements include, but are not limited to: the discount rate used in estimating the fair value of the lease right-of-use (ROU) assets and lease liabilities, the measurement of the Series D 2X liquidation preference, assumptions used in estimating the fair value of warrants and Purchase Rights issued, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, and assumptions used in estimating the fair value of stock-based compensation expense. The Company’s assumptions regarding the measurement of the First Closing Warrants, the Purchase Rights, the Series D 2X liquidation preference, the lease ROU assets and lease liabilities, and stock-based compensation are more fully described in </font><a style="font-family:inherit;font-size:10pt;" href="#sBC79643B17185F0693C47143E5BCD7AB"><font style="font-family:inherit;font-size:10pt;">Note 5 — Fair Value of Financial Instruments</font></a><font style="font-family:inherit;font-size:10pt;">, </font><a style="font-family:inherit;font-size:10pt;" href="#sB51A6C11D3D250B295793A7BC035B456"><font style="font-family:inherit;font-size:10pt;">Note 6 — Commitments and Contingencies</font></a><font style="font-family:inherit;font-size:10pt;">, and </font><a style="font-family:inherit;font-size:10pt;" href="#sC7C482F80A5A51FA8FAC381513289C6C"><font style="font-family:inherit;font-size:10pt;">Note 12 — Stock-based Compensation</font></a><font style="font-family:inherit;font-size:10pt;">. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001618835-19-000170-index-headers.html	Edgar Link	pending
0001618835-19-000170-index.html	Edgar Link	pending
0001618835-19-000170.txt	Edgar Link	pending
0001618835-19-000170-xbrl.zip	Edgar Link	pending
evfm-20190930.xml	Edgar Link	completed
evfm-20190930.xsd	Edgar Link	pending
evfm-20190930_cal.xml	Edgar Link	unprocessable
evfm-20190930_def.xml	Edgar Link	unprocessable
evfm-20190930_lab.xml	Edgar Link	unprocessable
evfm-20190930_pre.xml	Edgar Link	unprocessable
evfm-930201910xq.htm	Edgar Link	pending
evfm-9302019ex311.htm	Edgar Link	pending
evfm-9302019ex312.htm	Edgar Link	pending
evfm-9302019ex321.htm	Edgar Link	pending
exhibit101evofem_bioscienc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
wla800114v12kilroydel_image1.gif	Edgar Link	pending
wla800114v12kilroydel_image2.gif	Edgar Link	pending
wla800114v12kilroydel_image3.gif	Edgar Link	pending
wla800114v12kilroydel_image4.gif	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2019 Q4 Form 10-Q Financial Statement

#000161883519000170 Filed on November 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2019 Q4 Form 10-Q Financial Statement

#000161883519000170 Filed on November 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm